(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.8%.
Pelthos Therapeutics's earnings in 2025 is -$23,581,284.On average, 4 Wall Street analysts forecast PTHS's earnings for 2025 to be -$7,963,432, with the lowest PTHS earnings forecast at -$7,651,141, and the highest PTHS earnings forecast at -$8,197,651. On average, 4 Wall Street analysts forecast PTHS's earnings for 2026 to be -$4,840,518, with the lowest PTHS earnings forecast at -$7,201,074, and the highest PTHS earnings forecast at -$2,250,336.
In 2027, PTHS is forecast to generate $5,777,392 in earnings, with the lowest earnings forecast at $5,550,828 and the highest earnings forecast at $5,947,315.